Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Invivyd, Inc.NASDAQ: IVVD

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $513K fell 30.5% year over year, ahead of the -43.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 17.9% from the prior quarter. Over 3 fiscal years it compounded at +65.8% a year.

Context

  • Depreciation & amortization amounted to 3.9% of revenue in FY2025, down 8.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -30.5% holds above the trailing-twelve-month pace of -43.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$513K+17.9% QoQ
Last fiscal yearDec 2025
$2.11M-32.3% YoY
LTMMar 2026
$1.88M-43.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.5%——
1 year-32.3%——
3-year CAGR+65.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.11M USD
Year-over-year change
-32.3%
4-year CAGR
+577.5%

Depreciation & Amortization vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 depreciation & amortization of $1.88M is the 6th largest of the 10 companies compared; the peer median is $2.34M.
  • Its year-over-year change of -43.4% is the 8th highest of 9, against a peer median of +8.3%.
  • Depreciation & amortization amounts to 3.4% of revenue for IVVD, versus a peer median of 14.3%.
IVVD Competitors Peer median
Depreciation & Amortization for IVVD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$23.65M +1.1%+6.0%81.8%
CDXSCodexis, Inc.LTM Mar 2026$6.75M +171.1%-20.0%8.6%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$6.56M -25.2%-28.2%19.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.38M +84.9%+5.3%9.7%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.34M +35.9%-25.1%119.9%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M -43.4%+65.8%3.4%
TARAProtara Therapeutics, Inc.LTM Mar 2026$369K +11.1%+13.4%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K +5.4%+13.8%1.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$152K -97.9%——
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$142.16K ———
Peer median (excluding IVVD) $2.34M+8.3%+5.3%14.3%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Depreciation & Amortization1K462K2.03M3.11M2.11M
Deferred Income Tax00000
Stock-Based Compensation17.76M21.65M18.69M19.79M11.64M
Change in Working Capital22.79M(16.13M)5.89M(23.47M)(19.69M)
Accounts Receivables000(10.91M)(3.34M)
Inventory000(24.89M)(373K)
Accounts Payables(2.37M)(4.3M)6.47M2.42M3.21M
Other Working Capital25.16M(11.83M)(583K)9.91M(19.2M)
Other Non-Cash Items1.5M15.35M(1.12M)19.79M298K
Operating Cash Flow(184.74M)(219.99M)(173.16M)(170.49M)(58.14M)
Capital Expenditures(84K)(1.71M)(615K)(140K)(155K)
Acquisitions (Net)00000
Purchases of Investments(188.63M)(297.96M)(91.2M)00
Sales of Investments138M69M372.5M00
Other Investing Activities00000
Investing Cash Flow(50.71M)(230.67M)280.68M(140K)(155K)
Debt Repayment00000
Common Stock Issued330.91M510K1.2M39.29M215.63M
Common Stock Repurchased0(4K)(1K)00
Dividends Paid00000
Other Financing Activities(3.39M)510K1.05M46K0
Financing Cash Flow662.68M506K1.05M39.33M215.63M
Effect of Forex Changes0008K0
Net Change in Cash427.24M(450.15M)108.57M(131.29M)157.34M
Free Cash Flow(184.82M)(221.69M)(173.78M)(170.63M)(58.29M)

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.